Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;37(8):822-9.
doi: 10.1007/s00059-012-3707-9.

Familial dilated cardiomyopathy. Clinical and genetic characteristics

A Serio  1 , N Narula, T Kodama, V Favalli, E Arbustini
Affiliations

Familial dilated cardiomyopathy. Clinical and genetic characteristics

A Serio et al. Herz. 2012 Dec.

Abstract

Familial dilated cardiomyopathy (F-DCM) describes a clinically and genetically heterogeneous group of diseases, mostly inherited as autosomal dominant traits, having idiopathic left ventricular dilatation and dysfunction as a common phenotype. The age of onset, rate of progression, disease complications, as well as overall prognosis and outcome vary both amongst and within families. Clinical traits, both cardiac and extracardiac, may recur in association with the DCM phenotype. The former include conduction defects, structural abnormalities such as left ventricular noncompaction, of right ventricular involvement, and recurrence of atrial or ventricular arrhythmias; the latter commonly affect the musculoskeletal (myopathies/dystrophies, both clinically overt and subclinical), ocular, auditory, nervous, and integument systems. These traits may help guide genetic testing. In parallel to the clinical heterogeneity, F-DCM also shows genetic heterogeneity: more than 40 genes have been causally linked to F-DCM, with mutations recurring more commonly in a few known genes, and less frequently in rare, less commonly known genes. Based on the known prevalence of mutations in disease genes, more than 50% of F-DCM cases can be regarded as still genetically orphan, implying that further disease genes have to be discovered. Family screening and genetic testing are now established as the gold standard for diagnosis, care, and prevention in F-DCM. Diagnostic tests are performed using Sanger-based sequencing. Furthermore, new biotechnology tools, based on next-generation sequencing, are now being implemented in the research setting and will dramatically modify the future of the nosology of F-DCM.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Nat Genet. 2012 May 18;44(7):793-6 - PubMed
    1. Cardiol Rev. 1999 May-Jun;7(3):127-35 - PubMed
    1. J Am Coll Cardiol. 2002 Oct 16;40(8):1445-50 - PubMed
    1. J Child Neurol. 2002 Oct;17(10):759-65 - PubMed
    1. Am J Cardiol. 2009 Jan 15;103(2):262-5 - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources